GC Biopharma Statistics

Total Valuation

GC Biopharma has a market cap or net worth of KRW 1.49 trillion. The enterprise value is 2.54 trillion.

Market Cap	1.49T
Enterprise Value	2.54T

Important Dates

The last earnings date was Thursday, November 14, 2024.

Earnings Date	Nov 14, 2024
Ex-Dividend Date	n/a

Share Statistics

GC Biopharma has 11.41 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	11.41M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.95%
Owned by Institutions (%)	17.44%
Float	5.45M

Valuation Ratios

PE Ratio	n/a
Forward PE	48.04
PS Ratio	0.92
PB Ratio	1.19
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 24.16, with an EV/FCF ratio of -22.06.

EV / Earnings	-66.61
EV / Sales	1.57
EV / EBITDA	24.16
EV / EBIT	96.21
EV / FCF	-22.06

Financial Position

The company has a current ratio of 1.55, with a Debt / Equity ratio of 0.60.

Current Ratio	1.55
Quick Ratio	0.69
Debt / Equity	0.60
Debt / EBITDA	8.52
Debt / FCF	-7.78
Interest Coverage	0.75

Financial Efficiency

Return on equity (ROE) is -2.66% and return on invested capital (ROIC) is 0.72%.

Return on Equity (ROE)	-2.66%
Return on Assets (ROA)	0.62%
Return on Capital (ROIC)	0.72%
Revenue Per Employee	802.81M
Profits Per Employee	-18.95M
Employee Count	2,016
Asset Turnover	0.61
Inventory Turnover	2.05

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +18.87% in the last 52 weeks. The beta is 1.03, so GC Biopharma's price volatility has been similar to the market average.

Beta (5Y)	1.03
52-Week Price Change	+18.87%
50-Day Moving Average	156,366.00
200-Day Moving Average	131,388.00
Relative Strength Index (RSI)	27.48
Average Volume (20 Days)	59,408

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GC Biopharma had revenue of KRW 1.62 trillion and -38.20 billion in losses. Loss per share was -3,347.42.

Revenue	1.62T
Gross Profit	457.90B
Operating Income	26.44B
Pretax Income	-52.16B
Net Income	-38.20B
EBITDA	105.31B
EBIT	26.44B
Loss Per Share	-3,347.42

Full Income Statement

Balance Sheet

The company has 78.10 billion in cash and 897.68 billion in debt, giving a net cash position of -819.58 billion or -71,809.80 per share.

Cash & Cash Equivalents	78.10B
Total Debt	897.68B
Net Cash	-819.58B
Net Cash Per Share	-71,809.80
Equity (Book Value)	1.49T
Book Value Per Share	110,172.66
Working Capital	414.16B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -53.00 billion and capital expenditures -62.35 billion, giving a free cash flow of -115.35 billion.

Operating Cash Flow	-53.00B
Capital Expenditures	-62.35B
Free Cash Flow	-115.35B
FCF Per Share	-10,106.35

Full Cash Flow Statement

Margins

Gross margin is 28.29%, with operating and profit margins of 1.63% and -2.36%.

Gross Margin	28.29%
Operating Margin	1.63%
Pretax Margin	-3.22%
Profit Margin	-2.36%
EBITDA Margin	6.51%
EBIT Margin	1.63%
FCF Margin	-7.13%

Dividends & Yields

This stock pays an annual dividend of 1,500.00, which amounts to a dividend yield of 1.08%.

Dividend Per Share	1,500.00
Dividend Yield	1.08%
Dividend Growth (YoY)	-14.29%
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	1.08%
Earnings Yield	-2.56%
FCF Yield	-7.72%

Dividend Details

Stock Splits

The last stock split was on June 7, 2013. It was a forward split with a ratio of 1.05.

Last Split Date	Jun 7, 2013
Split Type	Forward
Split Ratio	1.05

Scores

GC Biopharma has an Altman Z-Score of 1.86. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.86
Piotroski F-Score	n/a